The popularity of Viagra initially drove a boom for pharma, nevertheless recent developments present a complicated outlook for investors. Generic versions are reducing revenue, and ongoing legal battles add further complexity to the equation. While certain companies may still see gains from adjacent offerings, the broader trend suggests a wary appr